IGM Biosciences (IGM Biosciences) Price-to-Tangible-Book : 2.88 (As of May. 03, 2024)

View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Price-to-Tangible-Book?

As of today (2024-05-03), IGM Biosciences's share price is $9.99. IGM Biosciences's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $3.46. Hence, IGM Biosciences's Price to Tangible Book Ratio of today is 2.88.

The historical rank and industry rank for IGM Biosciences's Price-to-Tangible-Book or its related term are showing as below:

IGMS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.4 Med: 3.89 Max: 7.39
Current: 2.89

During the past 7 years, IGM Biosciences's highest Price to Tangible Book Ratio was 7.39. The lowest was 2.40. And the median was 3.89.

IGMS's Price-to-Tangible-Book is ranked better than
50.33% of 1222 companies
in the Biotechnology industry
Industry Median: 2.75 vs IGMS: 2.89

A closely related ratio is called PB Ratio. As of today, IGM Biosciences's share price is $9.99. IGM Biosciences's Book Value per Sharefor the quarter that ended in Dec. 2023 was $3.46. Hence, IGM Biosciences's P/B Ratio of today is 2.88.

IGM Biosciences Price-to-Tangible-Book Historical Data

The historical data trend for IGM Biosciences's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Price-to-Tangible-Book Chart

IGM Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

4.84

7.39

3.89

2.55

2.40

IGM Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															2.55	2.48	1.88	1.92	2.40

Competitive Comparison of IGM Biosciences's Price-to-Tangible-Book

For the Biotechnology subindustry, IGM Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGM Biosciences's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGM Biosciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where IGM Biosciences's Price-to-Tangible-Book falls into.

IGM Biosciences Price-to-Tangible-Book Calculation

IGM Biosciences's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	9.99	/	3.463
	=	2.88

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

IGM Biosciences Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

IGM Biosciences (IGM Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (NAS:IGMS) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

1K0:Germany

Address

325 East Middlefield Road, Mountain View, CA, USA, 94043

Website

https://www.igmbio.com

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Executives

Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Fred Schwarzer	director, officer: CEO and President	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Bruce Keyt	officer: Chief Scientific Officer	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Lisa Lynn Decker	officer: Chief Business Officer	C/O ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
George Gauthier	officer: Chief Commercial Officer	C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Chris H Takimoto	officer: Chief Medical Officer	C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Misbah Tahir	officer: Chief Financial Officer	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Thompson Elizabeth H.z.	director	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Christina Teng Topsoe	director, 10 percent owner	325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Jakob Haldor Topsoe	director, 10 percent owner	325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Michael D Loberg	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Steven Weber	officer: Principal Accounting Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014